Welcome to our dedicated page for ACLARION news (Ticker: ACONW), a resource for investors and traders seeking the latest updates and insights on ACLARION stock.
Aclarion, Inc. (Nasdaq: ACON, ACONW) generates frequent news as a commercial-stage healthcare technology company focused on chronic low back pain diagnostics. The company’s updates center on its Nociscan SaaS platform, which uses Magnetic Resonance Spectroscopy (MRS), proprietary signal processing, biomarkers, and augmented intelligence algorithms to help physicians distinguish between painful and nonpainful lumbar discs.
News about Aclarion often highlights clinical and scientific milestones. These include progress in the pivotal CLARITY randomized trial, which evaluates whether incorporating Nociscan into surgical planning can improve outcomes for patients undergoing surgery for chronic low back pain, as well as publications of real-world evidence and peer-reviewed articles describing Nociscan’s clinical and economic value. Company announcements also cover participation in major spine and neuroscience meetings and recognition in digital health award programs.
Investors and clinicians following Aclarion can expect updates on market adoption, such as growth in Nociscan scan volumes, expansion of imaging centers and physician users, and developments in reimbursement, including private insurer coverage in the United Kingdom. Corporate news includes capital raises, balance sheet developments, executive appointments, and governance events reported through both press releases and SEC filings.
This news feed aggregates these items so readers can track how Aclarion advances its Nociscan platform, builds clinical evidence, and executes its commercial strategy in the diagnostic imaging and spine care space. For those monitoring ACON and ACONW, the page provides a centralized view of company announcements, clinical trial progress, and strategic updates over time.
Aclarion, a healthcare technology company, has appointed Dr. Christopher Ames as a Key Opinion Leader to enhance its Nociscan solution for chronic low back pain (cLBP). This SaaS platform is the first evidence-supported tool that helps physicians differentiate between painful and nonpainful discs in the lumbar spine. Dr. Ames emphasizes that the Nociscan tool will improve diagnostic clarity and patient outcomes. Additionally, Aclarion's Nociscan is included in a pivotal NIH-funded trial and has recently secured a new patent addressing painful disc degeneration.
Aclarion, a healthcare technology company, has appointed Dr. Eric Potts as a key opinion leader. Dr. Potts, a neurosurgeon, will assist in promoting Aclarion's Nociscan solution, which helps physicians identify chronic low back pain. Nociscan is the first SaaS platform to noninvasively distinguish between painful and nonpainful discs, leveraging chemical biomarkers. Aclarion aims to strengthen its clinical evidence and market support for this innovative approach, enhancing treatment strategies while addressing a major healthcare issue.
Aclarion, Inc. (ACON, ACONW) announced the appointment of Dr. Juan Uribe as a key opinion leader to enhance its efforts in chronic low back pain (cLBP) diagnostics. Dr. Uribe, renowned in spinal disorder research, will support Aclarion's objective of integrating clinical evidence and securing payer advocacy. The company's flagship Nociscan platform noninvasively identifies painful versus nonpainful lumbar discs using advanced biomarkers and algorithms. Aclarion aims to improve diagnostic accuracy and treatment strategies for cLBP, a leading cause of opioid addiction in the U.S.
Aclarion, Inc. (NASDAQ:ACON, ACONW), a healthcare technology company, presented at the 15th annual LD Micro Main Event on October 25, 2022. Executive Chairman Jeff Thramann delivered a company overview and business update. Aclarion focuses on chronic low back pain through its Nociscan platform, utilizing biomarkers and augmented intelligence to aid physicians in identifying pain sources in the lumbar spine. An updated investor presentation is available on their website, enhancing investor communications.
Aclarion, a healthcare technology company, has announced that Dr. Sigurd Berven will join as a key opinion leader to enhance the company's efforts in chronic low back pain diagnosis. Aclarion's Nociscan platform uniquely identifies painful discs using biomarkers and augmented intelligence. This technology aims to improve diagnostic accuracy and treatment strategies. Recently included in a NIH-funded trial, Nociscan further establishes its significance in the spine industry. Aclarion's focus is on robust clinical evidence and payer engagement to drive the adoption of its innovative solutions.
Aclarion announced its participation in the 37th Annual Meeting of the North American Spine Society (NASS), focusing on chronic low back pain (CLBP). The company's Nociscan platform, the first evidence-supported SaaS solution, assists in objectively analyzing intradiscal pain by utilizing biomarkers. Its role in the NIH HEAL Initiative highlights its significance in providing personalized pain assessment. Approximately 266 million people globally suffer from degenerative spine issues, making CLBP a critical healthcare concern.
Aclarion has appointed Dr. John Keller, Chief of Neurosurgery at University of Michigan Health-West, as a Key Opinion Leader in its strategy to enhance clinical evidence for its Nociscan solution, aimed at diagnosing chronic low back pain. Nociscan is a SaaS platform designed to distinguish between painful and non-painful lumbar discs using biomarkers and augmented intelligence. The initiative aligns with Aclarion's goal to secure payer community advocacy and expand its clinical utility evidence, including participation in a pivotal NIH-funded trial involving 200 patients.
Aclarion, a healthcare technology company, announced its participation in the Biomarkers for Evaluating Spine Treatments (BEST) Trial, funded by the NIH HEAL Initiative. This trial aims to optimize treatment for chronic low back pain (cLBP) using biomarkers, including Aclarion's proprietary Nociscan. The study will enroll over 800 patients across 12 academic institutions, with 200 receiving advanced biomarker profiling. The NIH HEAL Initiative supports this research to combat the opioid crisis through tailored cLBP treatments.
Aclarion has launched the Economic Value Analysis of Low back pain (EVAL) study to evaluate the financial impact of its Nociscan technology on chronic low back pain (CLBP) treatment. Conducted by the University of California, the study will assess the cost of care for CLBP patients, with initial findings expected in Q4 2022. Promising results indicate 87% of patients treated with Nociscan show significant improvements at two-year follow-ups, potentially influencing insurance coverage decisions. The study aims to demonstrate Nociscan's economic value, addressing the $134B annual cost of low back pain in the U.S.
Aclarion Inc. (NASDAQ: ACON, ACONW) announced promising two-year results from its pivotal clinical trial on Nociscan, showing that 87% of patients treated for chronic discogenic low back pain reported significant clinical improvement. Results will be discussed at the Annual State of Spine Surgery Think Tank in Mexico, along with a plan for future clinical studies. Aclarion aims to position Nociscan as the standard of care, leveraging its technology to distinguish painful discs and improve cost-effectiveness in treatment. Initial economic analysis results are expected in Q4 2022.